B-D-Galactose

B-D-Galactose

SCHEMBL2441804

OC[C@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 3/20 0.58
LGALS1 P09382 2/20 0.58
LGALS9 O00182 1/20 0.58
LGALS8 O00214 1/20 0.58
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
PYGB P11216 6/20 0.44
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
B-D-Galactose SCHEMBL9880688 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL10050866 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL13220216 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL18649521 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL8527882 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL23758905 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL17112445 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL79549 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL21123450 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12
B-D-Galactose SCHEMBL9820102 1.00 LGALS3 (0.58) LGALS3LGALS1LGALS9LGALS8CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408118-B1 ENZYMATIC METHOD OF PRODUCING 4-0-B-D GALACTOPYRANOSYL-D-XYLOSE, 4-0-B-D-GALACTOPYRANOSYL-D-XYLOSE OBTAINED USING SAID METHOD, COMPOSITIONS CONTAINING SAME AND THE USE THEREOF IN EVALUATING INTESTINAL LACTASE CONSEJO SUPERIOR INVESTIGACION (ES) 2006-03-29 EP claimed
US-5215591-A Free-flowing, pure and non-hygroscopic beta D-gulcopyranse BIOSPHERICS INCORPORATED (US) 1993-06-01 US claimed
CN-118184808-A Kidney bean soluble acidic polysaccharide and preparation method and application thereof 成都大学 2024-06-14 CN disclosed
CN-114641577-B Enzymatic process for the preparation of UDP-galactose 马克斯·普朗克科学促进学会 2023-06-23 CN disclosed
EP-2771696-B1 METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY INFANDX AG (DE) 2022-09-14 EP disclosed
CN-114641577-A Enzymatic process for the preparation of UDP-galactose 马克斯·普朗克科学促进学会 2022-06-17 CN disclosed
CN-114630911-A Enzymatic process for the preparation of UDP-GlcNAc 马克斯·普朗克科学促进学会 2022-06-14 CN disclosed
US-10588962-B2 Carbohydrate-glycolipid conjugate vaccines MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-03-17 US disclosed
US-10514383-B2 Diagnosis and treatment of neonatal encephalopathy INFANDX AG (DE) 2019-12-24 US disclosed
US-20150238597-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-08-27 US disclosed
US-20140308687-A1 Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy INFANDX AG (DE) 2014-10-16 US disclosed
US-8017673-B2 Polymer stabilizer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-13 US disclosed
US-20100179253-A1 POLYMER STABILIZER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-15 US disclosed
EP-2206740-A2 Polymer stabilizer Sumitomo Chemical Company, Limited (JP) 2010-07-14 EP disclosed
US-5215591-A Free-flowing, pure and non-hygroscopic beta D-gulcopyranse BIOSPHERICS INCORPORATED (US) 1993-06-01 US disclosed
US-5215591-A Free-flowing, pure and non-hygroscopic beta D-gulcopyranse BIOSPHERICS INCORPORATED (US) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179253-A1 POLYMER STABILIZER CNOT1, PARP1, FKBP1B LGALS3 3189/4885LGALS1 1798/4885LGALS9 2863/4885
US-20150238597-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES STT3B, STT3A, DDOST LGALS3 119/4885LGALS1 176/4885LGALS9 153/4885
US-10588962-B2 Carbohydrate-glycolipid conjugate vaccines STT3B, STT3A, DDOST LGALS3 119/4885LGALS1 176/4885LGALS9 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.